Meeting
2020 ASCO Virtual Scientific Program
Phase Ib study of decitabine in combination with gemcitabine in treatment of advanced soft tissue and bone sarcomas.
Authors
Varun Monga
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
Varun Monga , Rebecca Dodd , Amanda Scherer , Wade Robert Gutierrez , Munir Tanas , Sarah L. Mott , Mohammed M. Milhem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02959164
Citation
J Clin Oncol 38: 2020 (suppl; abstr 11550)
DOI
10.1200/JCO.2020.38.15_suppl.11550
Abstract #
11550
Poster Bd #
438
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of gemcitabine docetaxel combination in metastatic/unresectable locally advanced relapsed synovial sarcoma.
First Author: Ghazal Tansir
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
First Author: Victor Manuel Villalobos
Poster
2015 ASCO Annual Meeting
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
First Author: Andrew Eugene Hendifar
Poster
2014 ASCO Annual Meeting
Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.
First Author: Vivek Narasimhan